Drugs / C019199
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06220318 | Jul 2023 → Aug 2026 overdue | cancer | Fujian Haixi Pharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C019199 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06220318 ↗ |
| Route | Oral | “The C019199 will be taken orally, once a day” NCT06220318 ↗ |